Anupam Rasayan India Limited — Annual Report FY2026
Quality Scores
AI Summary
Anupam Rasayan (ANURAS) is a prominent Indian specialty chemical manufacturer focusing on multi-step synthesis and flow chemistry for global Life Science giants. Over the last five years, the company has scaled revenues at a 24% CAGR, shiftng towards a contract-intensive model. However, recent performance shows significant pressure on return ratios and cash flow sustainability. While it holds a strong position in Agrochemicals (65% of revenue), the recent capital-intensive expansion and the acquisition of Tanfac and interest in Bliss GVS indicate a shift in capital strategy. The stock…
Key Changes
The company has evolved from a conventional specialty chemical player into a sophisticated manufacturer focusing on flow chemistry and complex multi-step synthesis. Starting with a heavy reliance on Agrochemicals, it is actively diversifying into Pharmaceuticals and Personal Care to optimize margins and reduce sector-specific cyclicality. The 2026 commercialization of ETFA using flow chemistry marks a significant milestone, positioning the company as a global first-mover in that specific chemical process. Geographic expansion is evident through increased exports to MNCs in Japan, Europe, and North America. The business is clearly moving up the value chain from basic intermediates to high-complexity 'Key Starting Materials' (KSMs).
Management Commentary
Management has successfully onboarded several MNC customers and commercialized flow chemistry at scale, becoming a global first for certain molecules like ETFA. They exhibit high technical competency and vision in the specialty chemicals domain. However, there is a visible gap between the optimistic narrative in investor presentations and the actual cash flow generation. The management is transparent about their strategic roadmap but less focused on balance sheet deleveraging. Executive compensation is significant, and the frequent reliance on equity dilution (Equity Capital rising from ₹50 Cr to ₹146 Cr) reflects a heavy dependence on capital markets.
Financial Highlights
Revenue growth has been robust, rising from ₹502 Cr in FY19 to ₹2,365 Cr in FY26, yet this growth has come at the cost of balance sheet stability. Operating margins (OPM) have fluctuated between 19% and 28%, recently settling at 22% as the product mix evolves. Profitability (PAT) growth has lagged revenue growth over the 3-year period (-2% CAGR), indicating margin compression or rising fixed costs. High interest costs, which surged from ₹24 Cr in FY19 to ₹149 Cr in FY26, are severely eating into the bottom line. Tax rates have appeared inconsistent, often lower than the statutory rate, which management attributes to SEZ benefits.
Major Opportunities
- Market leader in Flow Chemistry in India
- Strong 5-year revenue CAGR of 24%
- Client base includes major global MNCs
Major Risks
- Persistent negative Free Cash Flow (FCF)
- Inventory days are exceptionally high (490-876 days)
- ROCE has declined to 7% from 13% peaks
Unlock the full report
Full 20+ sections, charts, AI chat with the report, and PDF export are available with Premium.